Results 151 to 160 of about 62,672 (281)

Hemophagocytic Lymphohistiocytosis Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of Spontaneous Reports. [PDF]

Cancers (Basel)
Guzel SS, Tay K, Cicek E, Jeral Evinc S, Atak S, Papila C, Demirci NS, Alan O.   +7 more
europepmc   +1 more source

Completion of the Icatibant Outcome Survey and What We Learned

Clinical &Experimental Allergy, EarlyView.
Laurence Bouillet, Werner Aberer, Teresa Caballero, Anete S. Grumach, Hilary J. Longhurst, Alissa Dangel, Natalie Khutoryansky, Irmgard Andresen, Andrea Zanichelli   +8 more
wiley   +1 more source

Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The results of this French Early Access Program were consistent with those reported in dupilumab randomized clinical trials in children aged 6 months–5 years with moderate‐to‐severe AD. This research offers insights into the practical use of dupilumab in routine clinical practice.
Audrey Lasek, Nathalia Bellon, Stéphanie Mallet, Hélène Aubert, Carine Vera, Lamia Achour, Claire Thénié, Randy Prescilla, Claire Abasq‐Thomas, Sébastien Barbarot   +9 more
wiley   +1 more source

Reply : Primary suspect drugs of cataracts in pediatric patients: FDA adverse events reporting database analysis. [PDF]

J Cataract Refract Surg
Khan SM, Abboud I, Elhusseiny AM, Elhusseiny AM.   +3 more
europepmc   +1 more source

Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety. [PDF]

Diabetes Metab Res Rev
ABSTRACT Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for metabolic disorders, but emerging safety concerns include alopecia and reproductive or endocrine‐related adverse events (AEs). This study investigated the association between specific GLP‐1 RAs and these endocrine‐related AEs using a large‐scale pharmacovigilance ...
Lee N, Kim Y.
europepmc   +2 more sources

Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Our findings show that greater proportions of litifilimab‐treated participants than placebo experienced 20%, 50%, 70% or 90% improvements in CLASI‐A score from baseline and CLASI‐A scores of 0–1 or 0–3. Similar results were observed using physician global assessments, supporting the Phase 2 LILAC study primary analysis in CLE.
Victoria P. Werth, Joseph F. Merola, Richard Furie, Kenneth Kalunian, Ronald F. van Vollenhoven, Juanita Romero‐Diaz, Qianyun Li, Weihong Yang, Catherine Barbey   +8 more
wiley   +1 more source

Incorporating patient-reported outcome measures into routine paediatric pharmacovigilance: opportunities for safety monitoring with practical use scenarios from paediatric oncology. [PDF]

Front Pharmacol
Teodoro P, Fernandes RM, Ribeiro I, Ferreira-da-Silva R.   +3 more
europepmc   +1 more source

Signals of Toxicity Associated With Gene Therapy: The Case of Etranacogene Dezaparvovec in the Treatment of Hemophilia B. [PDF]

J Pharm Technol
Castellana E, Chiappetta MR.
europepmc   +1 more source

European S2k guidelines on management of autoimmune blistering diseases in children and adolescents

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Autoimmune blistering disorders (AIBDs) in children are rare, challenging to diagnose and treat and often require immunosuppressants. Until now, no paediatric care guidelines existed. The EADV Task Force for AIBDs has developed the consensus‐based recommendations, enabling physicians to adopt a uniform, tailored treatment strategy to improve outcomes ...
A. Nanda, B. Tedbirt, C. Bodemer, M. C. Bolling, M. El Hachem, M. Nikolić, E. Benton, M. Caproni, D. De, D. Didona, K. Drenovska, M. Goebeler, M. Hertl, B. Horváth, M. Kasperkiewicz, D. Kiritsi, M. Larralde, A. V. Marzano, J. Meijer, D. F. Murrell, J. Powell, E. Sprecher, N. S. Chandran, M. M. Tomayko, S. Uzun, N. van Beek, H. Ott, A. Patsatsi, A. Torrelo, A. Welfringer‐Morin, E. Schmidt, P. Joly   +31 more
wiley   +1 more source

Correction: Model estimates of hospitalization discharge rates for norovirus gastroenteritis in Europe, 2004–2015

BMC Infectious Diseases
Elsa Negro-Calduch, Tom Cattaert, Thomas Verstraeten   +2 more
doaj   +1 more source